CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
IV fluorine-18 labeled methylcholine before PET/CTdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00928252
NCT00928252Phase 2Completed
CompareCT.gov

Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Queen's Medical Center·interventional·Posted Jun 25, 2009·Updated Aug 14, 2017

In Brief

A Phase 2 clinical trial evaluating IV fluorine-18 labeled methylcholine before PET/CT for Hormone Refractory Prostate Cancer. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether imaging with 18F-choline PET/CT can provide information that may help guide subsequent investigational or clinical treatments for patients with advanced (hormone-refractory) metastatic prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHormone Refractory Prostate Cancer
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 25, 2009
Enrollment StartJun 1, 2009
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 17.0 years ago

Interventions

IV fluorine-18 labeled methylcholine before PET/CTdrug

Intervention at pre-treatment, and at two timepoints post treatment intiation.